MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

PHR.US

8.32

-27.08%↓

MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

PHR.US

8.32

-27.08%↓

MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

PHR.US

8.32

-27.08%↓

MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

PHR.US

8.32

-27.08%↓

MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

PHR.US

8.32

-27.08%↓

Начало・Списък с акции・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Затворен

СекторЗдравеопазване

18.79 5.56

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

17.53

Максимум

18.84

Ключови измерители
By Trading Economics
Приходи	-14M -50M
Продажби	12M 128M
Марж на печалбата	-39.506
Служители	1,784
EBITDA	-17M -48M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+95.91% upside

Дивиденти
By Dow Jones
Следващи печалби	7.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-194M 2B
Предишно отваряне	13.23
Предишно затваряне	18.79

Настроения в новините

By Acuity

44%

56%

139 / 349 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

28.13 / 31.12 Подкрепа & съпротива

Zai Lab Ltd ADR Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

31.03.2026 г., 23:31 ч. UTC

Горещи акции

Stocks to Watch: Nike, RH, NCino

31.03.2026 г., 22:35 ч. UTC

Печалби

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1.04.2026 г., 00:00 ч. UTC

Придобивния, сливания и поглъщания

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31.03.2026 г., 23:50 ч. UTC

Придобивния, сливания и поглъщания

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31.03.2026 г., 23:43 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31.03.2026 г., 23:33 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31.03.2026 г., 23:21 ч. UTC

Печалби

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31.03.2026 г., 23:14 ч. UTC

Пазарно говорене

Печалби

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31.03.2026 г., 23:12 ч. UTC

Пазарно говорене

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31.03.2026 г., 22:36 ч. UTC

Печалби

China Vanke 2025 Loss Widens >000002.SZ

31.03.2026 г., 22:36 ч. UTC

Печалби

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31.03.2026 г., 22:36 ч. UTC

Печалби

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31.03.2026 г., 22:36 ч. UTC

Печалби

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31.03.2026 г., 22:36 ч. UTC

Печалби

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31.03.2026 г., 21:46 ч. UTC

Придобивния, сливания и поглъщания

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31.03.2026 г., 21:36 ч. UTC

Пазарно говорене

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31.03.2026 г., 21:35 ч. UTC

Печалби

Nike Expects China Sales Down 20% in 4Q, CFO Says

31.03.2026 г., 21:35 ч. UTC

Печалби

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31.03.2026 г., 21:35 ч. UTC

Печалби

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31.03.2026 г., 21:33 ч. UTC

Придобивния, сливания и поглъщания

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31.03.2026 г., 21:33 ч. UTC

Печалби

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31.03.2026 г., 21:32 ч. UTC

Печалби

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31.03.2026 г., 21:28 ч. UTC

Печалби

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31.03.2026 г., 21:26 ч. UTC

Печалби

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31.03.2026 г., 21:25 ч. UTC

Печалби

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31.03.2026 г., 21:24 ч. UTC

Пазарно говорене

Печалби

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31.03.2026 г., 21:22 ч. UTC

Печалби

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31.03.2026 г., 21:22 ч. UTC

Печалби

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31.03.2026 г., 21:21 ч. UTC

Печалби

Nike's Digital Channel Still Too Promotional, CFO Says

31.03.2026 г., 21:20 ч. UTC

Печалби

Nike CEO: Converse Remains Important to Portfolio

Сравнение с други в отрасъла

Ценова промяна

Zai Lab Ltd ADR Прогноза

Ценова цел

By TipRanks

95.91% нагоре

12-месечна прогноза

Среден 34.97 USD 95.91%

Висок 47 USD

Нисък 21.8 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Zai Lab Ltd ADR през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

6 ratings

Купи

Задържане

Продай

Според 6 анализатори, дали борсови рейтинги на Zai Lab Ltd ADR през последните 3 месеца.

Техническа оценка

By Trading Central

28.13 / 31.12Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Настроение

By Acuity

139 / 349 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.